Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC
Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Sponsor: Taizhou Mabtech Pharmaceutical Co.,Ltd
Terminated
Difficult to recruit subjects
Other Squamous Cell Carcinoma of the Head and Neck trials with similar outcome
- NCT03862066 · Nov 2021
- NCT03179956 · Phase EARLY_PHASE1 · Jan 2019
- NCT02429089 · Phase PHASE1 · Sep 2018
- NCT03246685 · Phase PHASE2 · Apr 2018
- NCT01305772 · Phase PHASE2 · May 2012
Browse all Squamous Cell Carcinoma of the Head and Neck trials
This PHASE1 trial investigates Squamous Cell Carcinoma of the Head and Neck and is currently terminated or withdrawn. Taizhou Mabtech Pharmaceutical Co.,Ltd leads this study, which shows 7 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
May 2024 — Jul 2024 [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
-
Jun 2023 — May 2024 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Mar 2023 — Jun 2023 [monthly]
Recruiting PHASE1
▶ Show 2 earlier versions
-
May 2022 — Mar 2023 [monthly]
Recruiting PHASE1
-
Jan 2021 — May 2022 [monthly]
Recruiting PHASE1
First recorded
Sep 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Taizhou Mabtech Pharmaceutical Co.,Ltd
For direct contact, visit the study record on ClinicalTrials.gov .